Aptar Digital Health announces a new collaboration with Gerresheimer to develop a tailored solution to support patients and health care professionals in cancer therapy management.
By connecting Aptar Digital Health's proprietary SaMD platform with Gx SensAir, Gerresheimer's on-body device for the subcutaneous delivery of large biologics molecules, this integrated solution is intended to improve overall treatment adherence and clinical outcomes.
More specifically, it aims to make remote patient monitoring easier, and facilitate the onboarding of patients to new therapies, helping them to better manage adverse effects.
Both companies believe that patient experience in oncology can be improved with innovative subcutaneous injection devices and digital platforms.
For pharmaceutical companies, this collaboration is an opportunity to offer a more patient-centric solution, and tackle potential challenges, such as treatment interruptions or discontinuations related to administration issues or adverse effects.
This solution will also support the transition from intravenous to subcutaneous administration of oncology drugs.
“We are honoured to collaborate with Gerresheimer, a global industrial partner in drug delivery devices,” stated Sai Shankar, President of Aptar Digital Health.
“By combining our collective and proprietary expertise in device and software engineering, we believe this collaboration has the potential to deliver innovative solutions for patients, healthcare providers and the healthcare industry.”
“Combining our efforts opens up new exciting possibilities for optimizing the respective drug therapy and improving the quality of life for cancer patients,” said Daniel Diezi, Vice President Digitalization and New Business Models at Gerresheimer.
“This collaboration in oncology will lay the groundwork for Aptar Digital Health and Gerresheimer to potentially expand into other therapeutic areas in the future.”
This integrated solution will first be designed for targeted anticancer therapies such as PD-1/PDL-1, CTLA-4, with the potential to expand to all therapies delivered subcutaneously.
